Dr Reddy’s Laboratories (DRL) acquired a majority of Wockhardt’s domestic formulations business for Rs 1,850 crore, underscoring the company’s commitment to the India market as it seeks to de-risk itself against regulatory pressure in the US. With this buyout, DRL is set to become the 11th largest pharmaceutical company in the Rs 14 lakh crore India market, up from 14.

(Economic Times)